Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients

Table 1

Demographic profile and characteristics of study participants.

	HC ()	RA 0DMARD ()	RA MTX ()
Age (years), median (IQR)	41.1 (35.9-56.5)	61.2 (43.1-68.0)	62.9 (58.3-66.7)
Female/male,	8/5 (61.5/38.5)	9/4 (69/31)	10/1 (91/9)
Age at debut of RA (years), median (IQR)	NA	41.3 (31.0-58.7)	59.4 (51.4-65.3)
Disease duration (years), median (IQR)	NA	5.5 (0.3-16.6)	0.3 (0.2-0.6)
Current smoker,	0 (0)	4 (31)	2 (18)
Ex-smoker,	3 (23)	2 (15)	5 (45)
Never smoker,	10 (77)	7 (54)	4 (36)
Radiographic changes, yes/no/no data, ^a	NA	6/6/1	4/5/2
Presence of subcutaneous nodules,	NA	3 (23)	0 (0)
RF positive,	—	10 (77)	11 (100)
ACPA positive,	—	11 (85)	5 (45)
DAS28 at MTX start, median (IQR)^b	NA	NA	5.6 (5.1-6.6)^e
DAS28 at vaccination, median (IQR)^b	NA	4.6 (3.1-5.2)	4.6 (3.6-5.6)
CRP at MTX start (mg/L), median (IQR)^c	NA	NA	8.8 (2.6-32.0)
CRP at vaccination (mg/L), median (IQR)^c	0.7 (0.6-1.2)	3.5 (1.6-7.0)	2.8 (1.6-8.9)
ESR at MTX start (mm), median (IQR)^d	NA	NA	51 (28-67)
ESR at vaccination (mm), median (IQR)^d	6 (3-13)	25 (16-43)	35 (12-45)
Prednisolone at vaccination,	0 (0)	2 (15)	5 (45)
-Dose in treated (mg/day), median (IQR)	NA	3.75 (2.5-5)	5 (2.5-10)
Methotrexate at vaccination (mg/week), median (IQR)	0 (0)	0 (0)	20 (15-25)

HC: healthy controls; RA: rheumatoid arthritis; 0DMARD: without disease-modifying antirheumatic drug treatment; MTX: methotrexate; IQR: interquartile range; NA: not applicable; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; DAS28: Disease Activity Score 28 joints examined; CRP: (P-CRP) C-reactive protein; ESR: (B-ESR) erythrocyte sedimentation rate. ^aFulfil criteria 7 in 1987 Rheumatoid Arthritis Classification. ^bOn a scale 0-10 high, 5.1-3.2 moderate, < 3.2-2.6 low disease activity, and < 2.6 remission. ^cReference . ^dReference (female), < 20 mm (male). ^e.